PYRIDORIN® (pyridoxamine dihydrochloride) is a novel small molecule drug candidate with a chemical structure similar to, but distinct from, vitamin B6 (pyridoxine). Unlike vitamin B6, pyridoxamine is regulated as an investigational drug candidate by the U.S. Food and Drug Administration.
The compound has a distinct structure and is comprised of a pyridine ring containing hydroxyl, methyl, aminomethyl, hydroxymethyl and phenol substituent groups.
This structure enables Pyridorin to preferentially bind to a variety of molecules which include:
• Scavenging activity toward free radical and carbonyl compounds that form during the breakdown of sugars and lipids that can lead to AGE formation;
• Trapping hydroxyl radicals (a highly reactive and short-lived neutral form of the hydroxide ion (HO−);
• Redox metal binding activity (e.g. copper (Cu2+), manganese (Mn2+), and iron (Fe2+)), which inhibits the oxidation of Amadori intermediates to AGEs.
• Inhibiting the break-down of glycated proteins to AGEs; and
• Blocking lipoxidation (lipid oxidation) by trapping lipoxidation intermediates